Canada House Wellness Group Announces Appointment of Michael Orrbrooke as President of Wholly Owned Subsidiary Abba Medix Cor...
July 08 2019 - 8:14AM
Canada House Wellness Group Inc. (CSE: CHV) (“
Canada
House” or the “
Company”), is pleased to
announce the appointment of Michael Orrbrooke as the President of
the Company’s wholly owned Licensed Producer, Abba Medix Corp.
(“
Abba”), effective immediately. Mr.
Orrbrooke also will continue in his role as the Company’s Chief
Revenue Officer.
As previously detailed in the Company’s press
release dated April 24, 2019, Mr. Orrbrooke has significant
experience in various executive roles within the Canadian cannabis
industry, both with an early stage applicant and a Tier 2 Licensed
Producer.
“Mike’s impact on Canada House as Chief Revenue
Officer cannot be overstated. He has extensive understanding of
cannabis production and our business model and has worked closely
with our team at Abba to successfully harvest our first crop,” said
Chris Churchill-Smith, CEO, Canada House. “The Abba harvests will
play a key role in Canada House’s projected revenues, particularly
as Abba works towards EU-GMP certification and develops domestic
and international sales channels. Mike’s brand and business
development experience in the cannabis and tobacco industries
compliment his roles as Canada House’s CRO and President of
Abba.”
“I am grateful for the opportunity to work with
this amazing team in a world class facility as we focus on
producing and distributing our quality grade cannabis,” said Mike
Orrbrooke, Chief Revenue Officer, Canada House and President, Abba
Medix Inc. “I am also excited about the downstream opportunities to
drive revenue and create shareholder value through the development
of Abba’s extraction and processing facility. The facility will
allow us to develop brands and products for cannabis consumers
worldwide.”
Concurrent with the appointment of Mr. Orrbrooke
as Abba’s President, the Company wishes to announce the departure
of Mr. Riley McGee. The Company thanks Mr. McGee for his service in
various capacities over the past three years.
About Canada House Wellness Group
Inc.Canada House Wellness Group Inc. is the parent company
of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that
produces high quality medical grade cannabis; Canada House Clinics
Inc., with clinics across the country that work directly with
primary care teams to provide specialized cannabinoid therapy
services to patients suffering from complex medical conditions; and
Knalysis Technologies, a provider of fully customizable,
cloud-based software that links physician, provider, and patient to
data that supports treatment with medical cannabis.
Canada House Wellness Group’s goal is to become
the leading cultivator of premium craft cannabis and provider of
cannabinoid therapy, targeting the medical cannabis markets
globally.
For more information please visit www.canadahouse.ca.
For further information, please
contact:
Liana Del Medico, Director of Communications &
Investor Relations Canada House Wellness Group
Inc.289-980-3584 liana.delmedico@canadahouse.ca
Cautionary Statement Regarding
Forward-Looking Information. This press release contains
forward-looking statements, including statements that relate to,
among other things, the Company’s clinic, production and technology
businesses, its future plans, the Company’s markets, objectives,
goals, strategies, intentions, beliefs, expectations and estimates,
and can generally be identified by the use of words such as “may”,
“will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”
and “continue” (or the negative thereof) and words and expressions
of similar import. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, such statements involve risks and uncertainties, and
undue reliance should not be placed on such statements. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Material assumptions used to develop forward-looking information in
this news release include, among other things, the regulations
related to cannabis use under the Access to Cannabis for Medical
Purposes Regulations and the act respecting cannabis and to amend
the Controlled Drugs and Substances Act, the Criminal Code and
other Acts, passed by the Canadian Federal government, making
cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of
additional capital resources to fund its activities; level of
competition; the ability to adapt products and services to the
changing market; the ability to attract and retain key executives;
and the ability to execute strategic plans. Additional information
about material factors that could cause actual results to differ
materially from expectations and about material factors or
assumptions applied in making forward-looking statements may be
found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as
in other public disclosure documents filed with Canadian securities
regulatory authorities. The Company does not undertake any
obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither the CSE nor its Regulation Services
Provider (as that term is defined in the policies of the CSE)
accepts responsibility for the adequacy or accuracy of this
release.
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From May 2024 to Jun 2024
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From Jun 2023 to Jun 2024